UTMD vs. CERS, ANIK, OSUR, CTSO, CODX, ATRI, ANGO, TLSI, RCEL, and ARAY
Should you be buying Utah Medical Products stock or one of its competitors? The main competitors of Utah Medical Products include Cerus (CERS), Anika Therapeutics (ANIK), OraSure Technologies (OSUR), Cytosorbents (CTSO), Co-Diagnostics (CODX), Atrion (ATRI), AngioDynamics (ANGO), TriSalus Life Sciences (TLSI), AVITA Medical (RCEL), and Accuray (ARAY). These companies are all part of the "surgical & medical instruments" industry.
Utah Medical Products (NASDAQ:UTMD) and Cerus (NASDAQ:CERS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.
Utah Medical Products has a beta of 0.15, suggesting that its stock price is 85% less volatile than the S&P 500. Comparatively, Cerus has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.
Utah Medical Products has higher earnings, but lower revenue than Cerus. Cerus is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.
69.6% of Utah Medical Products shares are owned by institutional investors. Comparatively, 78.4% of Cerus shares are owned by institutional investors. 6.6% of Utah Medical Products shares are owned by company insiders. Comparatively, 7.1% of Cerus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Cerus had 12 more articles in the media than Utah Medical Products. MarketBeat recorded 14 mentions for Cerus and 2 mentions for Utah Medical Products. Utah Medical Products' average media sentiment score of 0.20 beat Cerus' score of 0.04 indicating that Utah Medical Products is being referred to more favorably in the media.
Cerus received 416 more outperform votes than Utah Medical Products when rated by MarketBeat users. Likewise, 72.26% of users gave Cerus an outperform vote while only 61.29% of users gave Utah Medical Products an outperform vote.
Cerus has a consensus price target of $3.83, suggesting a potential upside of 107.21%. Given Cerus' higher probable upside, analysts clearly believe Cerus is more favorable than Utah Medical Products.
Utah Medical Products has a net margin of 33.40% compared to Cerus' net margin of -19.27%. Utah Medical Products' return on equity of 13.15% beat Cerus' return on equity.
Summary
Cerus beats Utah Medical Products on 9 of the 17 factors compared between the two stocks.
Get Utah Medical Products News Delivered to You Automatically
Sign up to receive the latest news and ratings for UTMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding UTMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Utah Medical Products Competitors List
Related Companies and Tools
